The Next Generation Genome Editing Market Size is predicted to develop with a CAGR of 21.8% during the forecast period for 2024-2031.
The Next Generation Genome Editing market is rapidly advancing with technologies that enhance the capabilities of CRISPR-Cas9, addressing its limitations and expanding its potential. These advancements provide improved precision, efficiency, and the ability to make large-scale DNA modifications. Key innovations include Bridge RNA, which facilitates large-scale insertions and rearrangements, and engineered Cas9 variants that enhance activity, broaden target ranges, and reduce immunogenicity.
The applications of these next-generation tools span various fields, including basic and clinical research for studying diseases like sickle cell and cancer, therapeutics for genetic and viral conditions, agriculture for developing resilient crops, and environmental applications for remediation and conservation. The market's growth is driven by the pursuit of more refined and versatile genetic engineering tools, as researchers seek to overcome the limitations of existing technologies, such as off-target effects and scalability challenges.
The next generation genome editing market is segmented by type of gene editing technique, application area, type of end user. By type of gene editing technique, the market is segmented recombinase-based editing, prime genome editing, bridge editing, base editing, retron library recombineering (RLR), transposon-based systems, homology-directed repair (HDR), and other emerging technologies. By application area market is categorized into drug discovery and development, diagnostics. By type of end user, the market is categorized into biotechnology companies, academic institutions, government laboratories, contract research organizations.
Base editing is significantly driving the Next Generation Genome Editing market due to its precision and safety advantages over traditional gene editing methods. This innovative technique allows for targeted alterations of single nucleotide bases in the DNA sequence without creating double-stranded breaks, which are common in other CRISPR-based methods. Ongoing advancements in base editing technologies, such as the development of modular systems for multiplex editing, are enhancing its applicability across fields like oncology, cardiology, and regenerative medicine. Companies are actively investing in base editing platforms to optimize research capabilities and therapeutic outcomes, which is expected to fuel market growth.
The Drug Discovery and Development segment within the Next Generation Genome Editing market is growing rapidly due to technological advancements, increased investment, and the rise of personalized medicine. CRISPR's simplicity and cost-effectiveness have revolutionized drug discovery by allowing efficient, targeted edits, accelerating the identification of drug targets and development of new therapies. Significant funding from public and private sectors supports research for novel treatments of genetic disorders and complex diseases. The segment also benefits from numerous clinical trials and the shift towards personalized medicine, enabling tailored therapies for individual genetic mutations, especially in oncology and rare genetic disorders.
North America's next generation genome editing market is boosted by a strong research infrastructure, high investment levels, and the presence of major industry players. The region's robust research ecosystem, comprising leading academic institutions and organizations, supports extensive R&D in genome editing, driving innovation and commercialization. Significant public and private investments, including government funding from agencies like the NIH, advance genome editing projects. Additionally, leading companies such as CRISPR Therapeutics, and Editas Medicine are at the forefront of developing and commercializing innovative CRISPR-based technologies, which are widely adopted in drug discovery and development.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 21.8 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Gene Editing Technique, Application Area, Type of End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Addgene, Beam Therapeutics, Bio Palette Co., Ltd, Caribou Biosciences, Cellectis, Creative Biogene, CRISPR Therapeutics, Danaher Corporation, EdiGene, Inc., Editas Medicine, ElevateBio, GenKOre, GenScript, Horizon Discovery Ltd., Inscripta, Inc, Integrated DNA Technologies (IDT), Intellia Therapeutics, KromaTiD, Inc, Maravai LifeSciences, Merck KGaA, Pairwise, Precision BioSciences, ProQR Therapeutics, QI-Biodesign, Recombinetics, Revvity, Sangamo Therapeutics, Inc., Scribe Therapeutics, Shape TX, Synthego, Synthorx (part of Sanofi) |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Next Generation Genome Editing Market Snapshot
Chapter 4. Global Next Generation Genome Editing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type of Gene Editing Technique Estimates & Trend Analysis
5.1. By Type of Gene Editing Technique & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Type of Gene Editing Technique:
5.2.1. Recombinase-Based Editing
5.2.2. Prime Genome Editing
5.2.3. Bridge Editing
5.2.4. Base Editing
5.2.5. Retron Library Recombineering (RLR)
5.2.6. Transposon-Based Systems
5.2.7. Homology-Directed Repair (HDR)
5.2.8. Other emerging technologies
Chapter 6. Market Segmentation 2: By Application Area Estimates & Trend Analysis
6.1. By Application Area & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Application Area:
6.2.1. Drug Discovery and Development
6.2.2. Diagnostics
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. By End User & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By End User:
7.2.1. Biotechnology Companies
7.2.2. Academic Institutions
7.2.3. Government Laboratories
7.2.4. Contract Research Organizations
Chapter 8. Next Generation Genome Editing Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.1.2. North America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.1.3. North America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.1.4. North America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.2.2. Europe Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.2.3. Europe Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.2.4. Europe Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.3.2. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.3.3. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.3.4. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.4. Latin America
8.4.1. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.4.2. Latin America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.4.3. Latin America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.4.4. Latin America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.5.2. Middle East & Africa Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.5.3. Middle East & Africa Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.5.4. Middle East & Africa Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Addgene
9.2.2. Beam Therapeutics
9.2.3. Bio Palette Co., Ltd
9.2.4. Caribou Biosciences
9.2.5. Cellectis
9.2.6. Creative Biogene
9.2.7. CRISPR Therapeutics.
9.2.8. Danaher Corporation
9.2.9. EdiGene, Inc.
9.2.10. Editas Medicine
9.2.11. ElevateBio
9.2.12. GenKOre
9.2.13. GenScript
9.2.14. Horizon Discovery Ltd.
9.2.15. Inscripta, Inc
9.2.16. Integrated DNA Technologies (IDT)
9.2.17. Intellia Therapeutics
9.2.18. KromaTiD, Inc
9.2.19. Maravai LifeSciences
9.2.20. Merck KGaA
9.2.21. Pairwise
9.2.22. Precision BioSciences
9.2.23. ProQR Therapeutics
9.2.24. QI-Biodesign
9.2.25. Recombinetics
9.2.26. Revvity
9.2.27. Sangamo Therapeutics, Inc.
9.2.28. Scribe Therapeutics
9.2.29. Shape TX
9.2.30. Synthego
9.2.31. Synthorx (part of Sanofi)
9.2.32. Other prominent players
Next Generation Genome Editing Market by Type of Gene Editing Technique -
Next Generation Genome Editing Market by Application Area -
Next Generation Genome Editing Market by Type of End User -
Next Generation Genome Editing Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
